Weighted Average Monthly Premium for Medicare Part D Stand-alone Prescription Drug Plans July 28, 2023 State Indicator
Key Facts About Medicare Part D Enrollment and Costs in 2023 July 26, 2023 Issue Brief The Medicare Part D program provides an outpatient prescription drug benefit to older adults and people with long-term disabilities in Medicare who enroll in private plans. This brief analyzes Medicare Part D enrollment and costs in 2023 and trends over time. The analysis highlights the substantial growth of Medicare Advantage drug plans in the marketplace for Part D drug coverage, where enrollment overall is concentrated in a handful of large plan sponsors.
What are the Implications of New Anti-Obesity Drugs for Racial Disparities? July 24, 2023 Blog This policy watch discusses some of the potential implications of the new anti-obesity drugs for racial equity.
10 Prescription Drugs Accounted for $48 Billion in Medicare Part D Spending in 2021, or More Than One-Fifth of Part D Spending That Year July 12, 2023 News Release A new KFF analysis finds that the 10 top-selling prescription drugs under Medicare Part D comprised less than 1 percent of all covered drugs in 2021, but accounted for 22 percent, or $48 billion, of gross Medicare Part D drug spending that year. The analysis provides context for understanding the…
A Small Number of Drugs Account for a Large Share of Medicare Part D Spending July 12, 2023 Issue Brief The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since 2018.
New Alzheimer’s Drugs Spark Hope for Patients and Cost Concerns for Medicare July 6, 2023 Blog The Food and Drug Administration granted full approval to Leqembi, a new Alzheimer’s drug, on July 6, 2023. This updated policy watch focuses on the implications of Medicare coverage of the drug for program spending as well as equity and affordability issues for beneficiaries, and the potential for the Inflation Reduction Act to address the spending impacts. It also covers additional details from the Centers for Medicare and Medicaid Services about patient registries.
June 14 Web Event: Probing the Power and Practices of Pharmacy Benefit Managers June 14, 2023 Event Pharmacy benefit managers (PBMs) are increasingly scrutinized intermediaries in the U.S. health care system, negotiating discounts on prescription medications for health insurers and employers while collecting rebates from drugmakers. Even as PBMs have taken on a larger role in drug coverage and pricing in recent decades, including through mergers with…
KFF Health Tracking Poll May 2023: Health Care in the 2024 Election and in the Courts May 26, 2023 Poll Finding Nearly a year after the Supreme Court overturned Roe v. Wade, this poll examines the public’s views of abortion and the Supreme Court, and knowledge about mifepristone, a medication abortion drug that is the subject of another court case, the ACA’s preventive services provision and HIV in the US.
About 1 in 20 People with Private Insurance Received Services that Could be Affected by a District Court Ruling Limiting the ACA’s Preventive Services Mandate May 25, 2023 News Release A new KFF analysis finds about 1 in 20 privately insured people (5.7%) received at least one ACA preventive service or drug that could be affected by a now-stayed U.S. District Court ruling in Braidwood Management v. Becerra, which found the Affordable Care Act’s (ACA) preventive services mandate partially unconstitutional.…
What is the Potential Impact of New Drugs for Obesity and Alzheimer’s Disease on Medicare Costs, Coverage and Beneficiaries? May 18, 2023 News Release Two new KFF analyses examine the potential impact of Medicare coverage of new prescription drugs for obesity and Alzheimer’s disease on program spending and beneficiary out-of-pocket costs, as well as the role that the Inflation Reduction Act could play in mitigating these effects. Manufacturers of both types of drugs are…